How Serious Are Moderna's FDA Delays?

The U.S. Food and Drug Administration (FDA) will take longer than expected to complete its review of Moderna's (NASDAQ: MRNA) Emergency Use Authorization (EUA) for its COVID-19 vaccine in adolescents ages 12 to 17. Moderna is pushing back its filing for EUA in younger children while this review moves forward. In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how serious these FDA delays are for Moderna.

Continue reading

Source Fool.com